355 related articles for article (PubMed ID: 32800099)
1. Effect of mammographic screening from age 40 years on breast cancer mortality (UK Age trial): final results of a randomised, controlled trial.
Duffy SW; Vulkan D; Cuckle H; Parmar D; Sheikh S; Smith RA; Evans A; Blyuss O; Johns L; Ellis IO; Myles J; Sasieni PD; Moss SM
Lancet Oncol; 2020 Sep; 21(9):1165-1172. PubMed ID: 32800099
[TBL] [Abstract][Full Text] [Related]
2. Annual mammographic screening to reduce breast cancer mortality in women from age 40 years: long-term follow-up of the UK Age RCT.
Duffy S; Vulkan D; Cuckle H; Parmar D; Sheikh S; Smith R; Evans A; Blyuss O; Johns L; Ellis I; Sasieni P; Wale C; Myles J; Moss S
Health Technol Assess; 2020 Oct; 24(55):1-24. PubMed ID: 33141657
[TBL] [Abstract][Full Text] [Related]
3. Effect of mammographic screening from age 40 years on breast cancer mortality in the UK Age trial at 17 years' follow-up: a randomised controlled trial.
Moss SM; Wale C; Smith R; Evans A; Cuckle H; Duffy SW
Lancet Oncol; 2015 Sep; 16(9):1123-1132. PubMed ID: 26206144
[TBL] [Abstract][Full Text] [Related]
4. Mortality impact, risks, and benefits of general population screening for ovarian cancer: the UKCTOCS randomised controlled trial.
Menon U; Gentry-Maharaj A; Burnell M; Ryan A; Kalsi JK; Singh N; Dawnay A; Fallowfield L; McGuire AJ; Campbell S; Skates SJ; Parmar M; Jacobs IJ
Health Technol Assess; 2023 May; ():1-81. PubMed ID: 37183782
[TBL] [Abstract][Full Text] [Related]
5. [Tailored Breast Screening Trial (TBST)].
Paci E; Mantellini P; Giorgi Rossi P; Falini P; Puliti D;
Epidemiol Prev; 2013; 37(4-5):317-27. PubMed ID: 24293498
[TBL] [Abstract][Full Text] [Related]
6. Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial.
Moss SM; Cuckle H; Evans A; Johns L; Waller M; Bobrow L;
Lancet; 2006 Dec; 368(9552):2053-60. PubMed ID: 17161727
[TBL] [Abstract][Full Text] [Related]
7. Two-view digital breast tomosynthesis versus digital mammography in a population-based breast cancer screening programme (To-Be): a randomised, controlled trial.
Hofvind S; Holen ÅS; Aase HS; Houssami N; Sebuødegård S; Moger TA; Haldorsen IS; Akslen LA
Lancet Oncol; 2019 Jun; 20(6):795-805. PubMed ID: 31078459
[TBL] [Abstract][Full Text] [Related]
8. Artificial intelligence-supported screen reading versus standard double reading in the Mammography Screening with Artificial Intelligence trial (MASAI): a clinical safety analysis of a randomised, controlled, non-inferiority, single-blinded, screening accuracy study.
Lång K; Josefsson V; Larsson AM; Larsson S; Högberg C; Sartor H; Hofvind S; Andersson I; Rosso A
Lancet Oncol; 2023 Aug; 24(8):936-944. PubMed ID: 37541274
[TBL] [Abstract][Full Text] [Related]
9. Screening mammography for women aged 40 to 49 years at average risk for breast cancer: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2007; 7(1):1-32. PubMed ID: 23074501
[TBL] [Abstract][Full Text] [Related]
10. Mammographic surveillance in women younger than 50 years who have a family history of breast cancer: tumour characteristics and projected effect on mortality in the prospective, single-arm, FH01 study.
FH01 collaborative teams
Lancet Oncol; 2010 Dec; 11(12):1127-34. PubMed ID: 21093374
[TBL] [Abstract][Full Text] [Related]
11. Effect of second timed appointments for non-attenders of breast cancer screening in England: a randomised controlled trial.
Allgood PC; Maroni R; Hudson S; Offman J; Turnbull AE; Peacock L; Steel J; Kirby G; Ingram CE; Somers J; Fuller C; Threlfall AG; Gabe R; Maxwell AJ; Patnick J; Duffy SW
Lancet Oncol; 2017 Jul; 18(7):972-980. PubMed ID: 28522311
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of mammographic surveillance services in women aged 40-49 years with a moderate family history of breast cancer: a single-arm cohort study.
Duffy SW; Mackay J; Thomas S; Anderson E; Chen TH; Ellis I; Evans G; Fielder H; Fox R; Gui G; Macmillan D; Moss S; Rogers C; Sibbering M; Wallis M; Warren R; Watson E; Whynes D; Allgood P; Caunt J
Health Technol Assess; 2013 Mar; 17(11):vii-xiv, 1-95. PubMed ID: 23489892
[TBL] [Abstract][Full Text] [Related]
13. Long-term effects of mammography screening: updated overview of the Swedish randomised trials.
Nyström L; Andersson I; Bjurstam N; Frisell J; Nordenskjöld B; Rutqvist LE
Lancet; 2002 Mar; 359(9310):909-19. PubMed ID: 11918907
[TBL] [Abstract][Full Text] [Related]
14. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial.
Menon U; Gentry-Maharaj A; Burnell M; Singh N; Ryan A; Karpinskyj C; Carlino G; Taylor J; Massingham SK; Raikou M; Kalsi JK; Woolas R; Manchanda R; Arora R; Casey L; Dawnay A; Dobbs S; Leeson S; Mould T; Seif MW; Sharma A; Williamson K; Liu Y; Fallowfield L; McGuire AJ; Campbell S; Skates SJ; Jacobs IJ; Parmar M
Lancet; 2021 Jun; 397(10290):2182-2193. PubMed ID: 33991479
[TBL] [Abstract][Full Text] [Related]
15. The Gothenburg Breast Screening Trial.
Bjurstam N; Björneld L; Warwick J; Sala E; Duffy SW; Nyström L; Walker N; Cahlin E; Eriksson O; Hafström LO; Lingaas H; Mattsson J; Persson S; Rudenstam CM; Salander H; Säve-Söderbergh J; Wahlin T
Cancer; 2003 May; 97(10):2387-96. PubMed ID: 12733136
[TBL] [Abstract][Full Text] [Related]
16. Mammography in combination with breast ultrasonography versus mammography for breast cancer screening in women at average risk.
Glechner A; Wagner G; Mitus JW; Teufer B; Klerings I; Böck N; Grillich L; Berzaczy D; Helbich TH; Gartlehner G
Cochrane Database Syst Rev; 2023 Mar; 3(3):CD009632. PubMed ID: 36999589
[TBL] [Abstract][Full Text] [Related]
17. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Adjunctive Ultrasonography for Breast Cancer Detection Among Women Aged 40-49 Years With Varying Breast Density Undergoing Screening Mammography: A Secondary Analysis of a Randomized Clinical Trial.
Harada-Shoji N; Suzuki A; Ishida T; Zheng YF; Narikawa-Shiono Y; Sato-Tadano A; Ohta R; Ohuchi N
JAMA Netw Open; 2021 Aug; 4(8):e2121505. PubMed ID: 34406400
[TBL] [Abstract][Full Text] [Related]
19. MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial.
Saadatmand S; Geuzinge HA; Rutgers EJT; Mann RM; de Roy van Zuidewijn DBW; Zonderland HM; Tollenaar RAEM; Lobbes MBI; Ausems MGEM; van 't Riet M; Hooning MJ; Mares-Engelberts I; Luiten EJT; Heijnsdijk EAM; Verhoef C; Karssemeijer N; Oosterwijk JC; Obdeijn IM; de Koning HJ; Tilanus-Linthorst MMA;
Lancet Oncol; 2019 Aug; 20(8):1136-1147. PubMed ID: 31221620
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
